目的：研究细辛的主治病证、配伍特点和常用剂量,为临床合理使用细辛提供参考。方法：收集历代中医方剂文献中含细辛的方剂,采用SQL Server 2008构建细辛方数据库,采用SPSS 19.0统计频数、均值等参数,运用SQL Server 2008开展数据的关...目的：研究细辛的主治病证、配伍特点和常用剂量,为临床合理使用细辛提供参考。方法：收集历代中医方剂文献中含细辛的方剂,采用SQL Server 2008构建细辛方数据库,采用SPSS 19.0统计频数、均值等参数,运用SQL Server 2008开展数据的关联分析。从内服和外用2个方面分析细辛方的主治病证范围、配伍特点及常用剂量。结果：共采集到4 489首含细辛的方剂;从内服和外用2个方面分别挖掘出了细辛方主治频数最高的前15个病证、配伍频数最高的前10味中药;确定细辛内服汤剂的常用剂量范围为1.85-13.75 g。结论：细辛的主治病证与药物配伍存在着明显的关联性;从汉朝至南北朝到清代呈现出依次递减的规律;细辛临床常用剂量以1.85-13.75 g为宜,针对不同的病证,可以配伍不同的方药、使用不同的剂量,不应受＂细辛不过钱＂的观点所束缚。展开更多
目的本文通过拟合调强放射治疗中危及器官(organ at risk,OAR)剂量公式,探究危及器官剂量的评估方法,从而相对精准地保障调强放疗计划的质量。方法选取2017年1月至2018年12月于西南医科大学附属医院肿瘤科接受调强放疗的乳腺癌保乳术后...目的本文通过拟合调强放射治疗中危及器官(organ at risk,OAR)剂量公式,探究危及器官剂量的评估方法,从而相对精准地保障调强放疗计划的质量。方法选取2017年1月至2018年12月于西南医科大学附属医院肿瘤科接受调强放疗的乳腺癌保乳术后病人(n=19)与鼻咽癌病人(n=55)的放疗计划,将OAR分割为多个子器官,子器官归一化后得到平均剂量均值,然后与各子器官到靶区表面最短距离轨迹图进行数据拟合得到相应拟合公式。结果显示不同OAR各子器官的归一化平均剂量均值与其到靶区表面最短距离呈负相关性;对上述因素进行拟合得出相应拟合公式,并评价该拟合公式取得了较好的拟合结果。结论本研究提出了一种较简便的调强放疗计划OAR剂量评估的方法,从而减少人为主观因素对OAR剂量的影响,提高调强放疗计划质量。展开更多
The purpose of this study was to compare the dose-volume statistics of stereotactic body radiotherapy (SBRT) for lung cancer between planning target volume (PTV): D95 and gross tumor volume (GTV): D99 dose prescriptio...The purpose of this study was to compare the dose-volume statistics of stereotactic body radiotherapy (SBRT) for lung cancer between planning target volume (PTV): D95 and gross tumor volume (GTV): D99 dose prescriptions using Monte Carlo (MC) calculation. Plans for 183 patients treated between October 2010 and April 2013 were generated based on four-dimensional (4D) computed tomography (CT) under free breathing. A uniform margin of 8 mm was added to the internal target volume (ITV) to generate PTV. A leaf margin of 2 mm was added to the PTV. The plans were calculated with two different dose prescription methods: 40 Gy to cover 95% of the PTV (PTV prescription) and 44 Gy to cover 99% of the GTV (GTV prescription). A 6-MV photon beam was used. A dose-volume histogram (DVH) analysis was performed for dose to the GTV using PTV and GTV dose prescriptions. For each treatment plan, we evaluated the minimum dose to 99% of the GTV (D99). The D99 of GTV was 44.5 ± 1.9 Gy and 44.0 ± 0.0 Gy for PTV and GTV prescriptions, respectively. The dose to the GTV had wide variations with PTV prescription. We recommend that GTV based dose prescription should be used to standardize dose to the tumor and to achieve highly conformal dose distributions in SBRT for lung cancer.展开更多
文摘目的：研究细辛的主治病证、配伍特点和常用剂量,为临床合理使用细辛提供参考。方法：收集历代中医方剂文献中含细辛的方剂,采用SQL Server 2008构建细辛方数据库,采用SPSS 19.0统计频数、均值等参数,运用SQL Server 2008开展数据的关联分析。从内服和外用2个方面分析细辛方的主治病证范围、配伍特点及常用剂量。结果：共采集到4 489首含细辛的方剂;从内服和外用2个方面分别挖掘出了细辛方主治频数最高的前15个病证、配伍频数最高的前10味中药;确定细辛内服汤剂的常用剂量范围为1.85-13.75 g。结论：细辛的主治病证与药物配伍存在着明显的关联性;从汉朝至南北朝到清代呈现出依次递减的规律;细辛临床常用剂量以1.85-13.75 g为宜,针对不同的病证,可以配伍不同的方药、使用不同的剂量,不应受＂细辛不过钱＂的观点所束缚。
文摘目的本文通过拟合调强放射治疗中危及器官(organ at risk,OAR)剂量公式,探究危及器官剂量的评估方法,从而相对精准地保障调强放疗计划的质量。方法选取2017年1月至2018年12月于西南医科大学附属医院肿瘤科接受调强放疗的乳腺癌保乳术后病人(n=19)与鼻咽癌病人(n=55)的放疗计划,将OAR分割为多个子器官,子器官归一化后得到平均剂量均值,然后与各子器官到靶区表面最短距离轨迹图进行数据拟合得到相应拟合公式。结果显示不同OAR各子器官的归一化平均剂量均值与其到靶区表面最短距离呈负相关性;对上述因素进行拟合得出相应拟合公式,并评价该拟合公式取得了较好的拟合结果。结论本研究提出了一种较简便的调强放疗计划OAR剂量评估的方法,从而减少人为主观因素对OAR剂量的影响,提高调强放疗计划质量。
文摘The purpose of this study was to compare the dose-volume statistics of stereotactic body radiotherapy (SBRT) for lung cancer between planning target volume (PTV): D95 and gross tumor volume (GTV): D99 dose prescriptions using Monte Carlo (MC) calculation. Plans for 183 patients treated between October 2010 and April 2013 were generated based on four-dimensional (4D) computed tomography (CT) under free breathing. A uniform margin of 8 mm was added to the internal target volume (ITV) to generate PTV. A leaf margin of 2 mm was added to the PTV. The plans were calculated with two different dose prescription methods: 40 Gy to cover 95% of the PTV (PTV prescription) and 44 Gy to cover 99% of the GTV (GTV prescription). A 6-MV photon beam was used. A dose-volume histogram (DVH) analysis was performed for dose to the GTV using PTV and GTV dose prescriptions. For each treatment plan, we evaluated the minimum dose to 99% of the GTV (D99). The D99 of GTV was 44.5 ± 1.9 Gy and 44.0 ± 0.0 Gy for PTV and GTV prescriptions, respectively. The dose to the GTV had wide variations with PTV prescription. We recommend that GTV based dose prescription should be used to standardize dose to the tumor and to achieve highly conformal dose distributions in SBRT for lung cancer.
